Cardiogenic Shock
219
70
77
61
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Research Maturity
61 completed trials (28% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
3.2%
7 terminated out of 219 trials
89.7%
+3.2% vs benchmark
10%
22 trials in Phase 3/4
8%
5 of 61 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 61 completed trials
Clinical Trials (219)
Multimodal Phenotyping In Patients Referred With Acute Cardiac faiLurE
Evaluation of Oxiris Membrane as a Treatment for Ischemia-reperfusion Syndrome in Cardiogenic Shock Treated With Extracorporeal Life Support (ECMO/ECLS): A Randomized Pilot Study ECMORIX
Magenta Elevate™ Clinical Feasibility Study in Cardiogenic Shock
COMPARE-VENT Feasibility Pilot Study
CRP Apheresis in Infarct-Related Cardiogenic Shock
Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO
Abiomed Impella RT-DAQ - Observational Study
BEAT-SHOCK Registry
Cardiovascular Outcomes Registry in Cardiogenic SHOCK (COR-SHOCK)
OPTIMIZE 5.5 - Optimizing Impella 5.5 Outcomes Through Advanced Data Science
Oxygen Delivery Index (ODIN) Study
Low Dose of Hydrocortisone and Fludrocortisone in Adult Cardiogenic Shock.
Altshock-2 REGISTRY
Randomized Evaluation of Istaroxime for Stabilization in Acute Heart Failure-Cardiogenic Shock
Feasibility of Protocolised Analgosedation in ECMO
Catheter-Oriented Unloading and Recovery With a Left Ventricular Assist Gear: Efficacy in Post Cardiotomy Cardiogenic Shock
Improving Sedation Practice in Critically Ill Adult Patients Using a Co-designed Sedation Protocol
Transcatheter Mitral Valve Repair for Inotrope Dependent Cardiogenic Shock
Augmented Pacing for Shock in the Cardiac Intensive Care Unit
Platelet Function and Impella Support